Analysis: Alimta patent seen as Lilly's "wild card"
NEW YORK (Reuters) - Eli Lilly & Co may have a $15 billion wild card up its sleeve as it waits for desperately needed new drugs to bear fruit.
Source: http://goo.gl/mag/PXA6K8Q
Analysis: Alimta patent seen as Lilly's "wild card"
NEW YORK (Reuters) - Eli Lilly & Co may have a $15 billion wild card up its sleeve as it waits for desperately needed new drugs to bear fruit.
Source: http://goo.gl/mag/PXA6K8Q
No comments:
Post a Comment